Lung Cancer

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.